Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Int J Rehabil Res ; 40(4): 333-338, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28777127

RESUMEN

Vestibular rehabilitation using individualized vibrotactile neurofeedback training (IVNT) can lead to significant improvement in the postural stability of patients with vestibular symptoms of different origins. However, some of these patients have complex, severe dizziness, meaning that a pharmacological pretreatment or parallel (to vestibular rehabilitation) treatment can help them perform the rehabilitation exercises. Hence, the present study investigated the influence of a pharmacological treatment on the efficacy of vibrotactile neurofeedback training in patients with chronic, noncompensated vestibulopathies. All participants performed IVNT for ∼10 min each day for 2 weeks. In addition, every second participant was selected randomly to receive oral medication (20 mg cinnarizine and 40 mg dimenhydrinate per tablet), taking three tables per day. Trunk and ankle sway and postural stability were measured. In addition, the dizziness handicap inventory was evaluated immediately before training on the last day of training and 6 months after training. After the 10-day period of IVNT, both groups showed a statistically significant improvement in all parameters tested. A follow-up analysis after 6 months showed a long-term efficacy for the IVNT, that is, the patients remained significantly improved in their postural stability. The antivertiginous therapy did not hinder the efficacy of the IVNT. The present results indicate that IVNT even in combination with an antivertiginous drug therapy is an effective treatment regime for patients with disabling vertigo of different origins.


Asunto(s)
Antieméticos/uso terapéutico , Neurorretroalimentación , Vértigo/terapia , Anciano , Cinarizina/uso terapéutico , Dimenhidrinato/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad
2.
Int Tinnitus J ; 14(1): 69-72, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18616089

RESUMEN

From 2001 to 2006, we performed a retrospective study of patients suffering from chronic unilateral or bilateral tinnitus that was previously ineffectively treated by oral drugs [betahistine (Betaserc), extract of Ginkgo biloba (EGb 761), tanakan (Tebokan), and cinnarizine-dimenhydrinate (Arlevert), singly or in combination]. We divided 150 tinnitus patients (80 men, 70 women) into seven treatment groups. Treatments consisted of application of intravenous pentoxifylline, lidocaine, or vinpocetine (Cavinton) and combination of these agents with physiotherapy and soft laser. Mean duration (+/- standard deviation) of tinnitus in these patients was 7.4 +/- 6.0 years; their mean age was 55.6 +/- 12.5 years. The aim of our study was to compare treatment modalities and define their effectiveness for tinnitus relief. The most effective treatment was defined as a combination of Cavinton and physiotherapy. We evaluated pure lidocaine infusion therapy as ineffective. None of the treatment modalities had an objective correlate of improvement, though improvement was reported by a visual analog scale.


Asunto(s)
Acúfeno/rehabilitación , Adulto , Anciano , Betahistina/uso terapéutico , Enfermedad Crónica , Cinarizina/uso terapéutico , Terapia Combinada , Dimenhidrinato/uso terapéutico , Combinación de Medicamentos , Quimioterapia Combinada , Femenino , Ginkgo biloba , Humanos , Lidocaína/uso terapéutico , Terapia por Luz de Baja Intensidad , Masculino , Persona de Mediana Edad , Pentoxifilina/uso terapéutico , Modalidades de Fisioterapia , Extractos Vegetales/uso terapéutico , Estudios Retrospectivos , Alcaloides de la Vinca/uso terapéutico
3.
Forensic Sci Int ; 179(2-3): e57-61, 2008 Aug 06.
Artículo en Inglés | MEDLINE | ID: mdl-18621494

RESUMEN

A 26-year-old male came to hospital around midnight complaining about muscle pain of the extremities as well as the tongue and slightly raised temperature. He reported the intake of an unknown amount of sinicuichi tea he had fermented over 24 h by adding yeast and sugar. The patient was treated with Vomex A (dimenhydrinate) and released from hospital the following afternoon. A blood sample taken shortly after submission and a small amount of the used plant material were available for analysis. Herbal drugs are widely used as stimulants as a legal alternative to illegal psychoactive drugs or in traditional context. Among many others like Sassafras officinalis, Salvia divinorum or Ephedra, Heimia salicifolia ("sinicuichi"), a species of the lythraceae family, is available via several online shops. Brewed up or fermented and consumed, the so-called sinicuichi tea may cause exhilarating feelings and an alteration of awareness accompanied by bradycardia, relaxation of the muscles and a pleasant faintness. Therefore Sinicuichi brew and heimia leaves are widely used for medication by the natives of Central and South America. After liquid extraction with acetone five different alkaloids were detected in the plant material by LC-MS/MS operated in the Q1 scan mode applying a TurboIonSpray source. Subsequently, Product Ion Spectra were recorded and after confirming the molecular formula by determining the accurate masses, possible structures of H. salicifolia alkaloids were assigned. The information of the Product Ion Spectra was then used to set up a sensitive multiple reaction monitoring (MRM) method. Applying the MRM method to the patient's serum sample after alkaline liquid-liquid extraction all of the five heimia alkaloids detected in the plant material were also detected qualitatively in the serum extract, confirming the ingestion.


Asunto(s)
Alcaloides/sangre , Bebidas , Lythraceae , Extractos Vegetales/efectos adversos , Adulto , Antieméticos/uso terapéutico , Cromatografía Liquida , Dimenhidrinato/uso terapéutico , Fiebre/inducido químicamente , Toxicología Forense , Cefalea/inducido químicamente , Humanos , Masculino , Náusea/inducido químicamente , Dolor/inducido químicamente , Espectrometría de Masas en Tándem , Vómitos/inducido químicamente
4.
J Med Assoc Thai ; 90(9): 1703-9, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17957907

RESUMEN

OBJECTIVE: To study the efficacy of ginger and dimenhydrinate in the treatment of nausea and vomiting in pregnancy. STUDY DESIGN: Double blind randomized controlled trial. SETTING: Department of Obstetrics and Gynecology, Thammasat Hospital, Faculty of Medicine, Thammasat University. MATERIAL AND METHOD: Between January 2005 and December 2005, 170 pregnant women who attended at antenatal clinic Thammasat University Hospital with the symptoms of nausea and vomiting in pregnancy were randomly allocated into group A (n = 85) and group B (n = 85). The patients in group A received one capsule of ginger twice daily (one capsule contained 0.5 gm of ginger powder) while the patients in group B received the identical capsule of 50 mg dimenhydrinate twice daily. The visual analogue nausea scores (VANS) and vomiting times were evaluated at day 0-7 of the treatment. RESULTS: There was no significant difference in the visual analogue nausea scores (VANS) between group A and group B in day 1-7 of the treatment. The vomiting episodes of group A were greater than group B during the first and second day of the treatment with statistically significant difference. No difference in vomiting episodes during the day 3-7 of treatment was found in both groups. There was a statistically significant difference in the side effect of drowsiness after treatment in group B greater (77.64%) than group A (5.88%) (p < 0.01). CONCLUSION: From the presented data, ginger is as effective as dimenhydrinate in the treatment of nausea and vomiting during pregnancy and has fewer side effects.


Asunto(s)
Antieméticos/uso terapéutico , Dimenhidrinato/uso terapéutico , Náusea/tratamiento farmacológico , Complicaciones del Embarazo/tratamiento farmacológico , Resultado del Tratamiento , Vómitos/tratamiento farmacológico , Zingiber officinale , Adulto , Antieméticos/farmacología , Dimenhidrinato/farmacología , Femenino , Humanos , Embarazo , Perfil de Impacto de Enfermedad
5.
Voen Med Zh ; 327(1): 55-9, 96, 2006 Jan.
Artículo en Ruso | MEDLINE | ID: mdl-16544756

RESUMEN

Anti-sea-sickness effect of a new homeopathic drug [see text] and its influence on operator's working capacity during Coriolis acceleration was evaluated in blind placebo-controlled investigation conducted in practically healthy volunteers with low vestibular resistance. For comparison "Dimenhydrinate" was used. The investigation has demonstrated that [see text] has rather strong anti-sea-sickness effect, is comparable with dimenhydrinate effectiveness and prevents the development of disorders in sensory-and-motor and cognitive functions during the influence of static-and- kinetic loads. According to the data obtained the protective action of [see text] is most likely connected with adaptive effect on organs and systems that form the functional protective system against sea-sickness. The negative influence of the drug on CNS complex functions was not observed that allows recommending its prophylactic use in subjects with low sea-sickness resistance including the operators.


Asunto(s)
Homeopatía/métodos , Materia Medica/uso terapéutico , Mareo por Movimiento/prevención & control , Adolescente , Adulto , Dimenhidrinato/administración & dosificación , Dimenhidrinato/uso terapéutico , Femenino , Humanos , Masculino , Materia Medica/administración & dosificación , Persona de Mediana Edad , Personal Militar , Síndrome , Resultado del Tratamiento
6.
Med Klin (Munich) ; 101(11): 886-90, 2006 Nov 15.
Artículo en Alemán | MEDLINE | ID: mdl-17235475

RESUMEN

PURPOSE: In this decision-tree analysis, the costs of otogenic vertigo treatment were investigated from the third-party payer's perspective. Either the combination preparation, with cinnarizine 20 mg and dimenhydrinate 40 mg as active substances, or betahistine (12 mg betahistinedimesilate) was administered. METHODS: A core model, based on clinical studies, was developed and a cost-effectiveness analysis was conducted. Both differences in effectiveness of the alternative treatments and adverse reactions and side effects were included. The number of cases, in which no more symptoms of dizziness were detected after 4 weeks of therapy, served as the effectiveness parameter. RESULTS: The effectiveness-adjusted costs amounted to 130.11 Euros for patients treated with the combination preparation and 629.28 Euros for treatment with betahistine. CONCLUSION: From the third-party payer's perspective, therapy of otogenic vertigo with the combination preparation is more cost-effective than a treatment with betahistine. From the patient's perspective, the higher effectiveness and the superior profile of side effects militate in favor of a therapy with the combination preparation.


Asunto(s)
Betahistina/economía , Cinarizina/economía , Dimenhidrinato/economía , Costos de los Medicamentos/estadística & datos numéricos , Agonistas de los Receptores Histamínicos/economía , Enfermedad de Meniere/economía , Adulto , Betahistina/efectos adversos , Betahistina/uso terapéutico , Cinarizina/efectos adversos , Cinarizina/uso terapéutico , Análisis Costo-Beneficio , Árboles de Decisión , Dimenhidrinato/efectos adversos , Dimenhidrinato/uso terapéutico , Combinación de Medicamentos , Medicina Basada en la Evidencia , Femenino , Agonistas de los Receptores Histamínicos/efectos adversos , Agonistas de los Receptores Histamínicos/uso terapéutico , Humanos , Masculino , Enfermedad de Meniere/tratamiento farmacológico , Programas Nacionales de Salud/economía
7.
Arzneimittelforschung ; 55(1): 23-9, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15727161

RESUMEN

The increasing interest in alternative medical practices has led to a number of controlled studies on herbal and homeopathic agents. This paper presents the results of a meta-analysis of four recent clinical trials evaluating the homeopathic preparation Vertigoheel (VH) compared with usual therapies (betahistine, Ginkgo biloba extract, dimenhydrinate) for vertigo in a total of 1388 patients. Two trials were observational studies and the other two were randomised double-blind controlled trials. The duration of treatment (6-8 weeks) and dosage were comparable in all studies. Treatments were evaluated for the variables "number of vertigo episodes", "intensity of episodes" and "duration of episodes". As the studies differed in the age of patients and in the baseline values of vertigo, the individual reductions of number, intensity and duration of episodes were adjusted on equal age and baseline values (total means). An analysis of variance (with studies as random effects) showed no relevant influence of studies on the adjusted reductions and no relevant interaction between studies and treatment effects. The meta-analysis of all four trials showed equivalent reductions with VH and with control treatment: mean reduction of the number of daily episodes 4.0 for VH and 3.9 for control (standard error 0.11 for both groups); mean reduction of the duration (on a scale 0-4) for VH 1.1 and for the control 1.0 (standard error 0.03 for both groups); mean reduction of the intensity (on a scale 0-4) for VH 1.18 and for the control 1.8 (standard error 0.03 for both groups). In the non-inferiority analysis from all trials, VH was non-inferior in all variables. The results show the applicability of meta-analyses on the data from studies with homeopathicdrugs and support the results from the individual studies indicating good efficacy and tolerability of VH in patients with vertigo.


Asunto(s)
Materia Medica/uso terapéutico , Minerales/uso terapéutico , Picrotoxina/uso terapéutico , Extractos Vegetales/uso terapéutico , Vértigo/tratamiento farmacológico , Betahistina/efectos adversos , Betahistina/uso terapéutico , Dimenhidrinato/efectos adversos , Dimenhidrinato/uso terapéutico , Combinación de Medicamentos , Ginkgo biloba , Agonistas de los Receptores Histamínicos/efectos adversos , Agonistas de los Receptores Histamínicos/uso terapéutico , Humanos , Materia Medica/efectos adversos , Minerales/efectos adversos , Satisfacción del Paciente , Picrotoxina/efectos adversos , Extractos Vegetales/efectos adversos , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento
8.
Graefes Arch Clin Exp Ophthalmol ; 238(1): 59-63, 2000 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-10664054

RESUMEN

OBJECTIVE: The purpose of this study was to evaluate the antiemetic effect of prophylactic dimenhydrinate application prior to Faden operation and to compare the incidence of PONV between bimedial Faden operation (BMF) and horizontal recess-resect procedure (R&R). METHODS: Ninety-nine children (4-10 years) scheduled for BMF were included in this prospective double-blind study. Midazolam (0.5 mg/kg body weight, BW) was administered orally for premedication 30 min before induction of anesthesia. Additionally, children weighing >/=23 kg received either dimenhydrinate suppositories or placebo. The placebo group was compared with 148 children who underwent R&R surgery without antiemetic prophylaxis during the same period. Anesthesia was induced with thiopentone (5-10 mg/kg BW) and vecuronium (0.1 mg/kg BW) bromide and maintained with halothane (1-2 vol%) in N(2)O/O(2) (65/35 vol%). Age, height, weight, and incidence of oculocardiac reflex were documented. PONV was classified into "no vomiting", "vomiting without therapy", and "vomiting requiring rescue medication". In the latter case dimenhydrinate was given again. The chi-square test was used for statistical analysis. RESULTS: Forty-eight patients received placebo, while 51 received dimenhydrinate. No differences between any groups were observed concerning age, height, weight, and incidence of oculocardiac reflex. Compared to R&R surgery, PONV requiring rescue medication occurred significantly more frequently after BMF (45% vs 23% after R&R). PONV after BMF was significantly less severe in the dimenhydrinate group than in the placebo group. The total incidence of PONV after BMF, however, was not significantly reduced. CONCLUSION: The high incidence of PONV after BMF can be explained by the greater invasiveness of BMF than R&R surgery. PONV requiring antiemetic rescue medication can be reduced by preoperative administration of dimenhydrinate suppositories.


Asunto(s)
Antieméticos/uso terapéutico , Dimenhidrinato/uso terapéutico , Músculos Oculomotores/cirugía , Procedimientos Quirúrgicos Oftalmológicos/efectos adversos , Náusea y Vómito Posoperatorios/prevención & control , Estrabismo/cirugía , Anestesia Local/métodos , Antieméticos/administración & dosificación , Niño , Preescolar , Dimenhidrinato/administración & dosificación , Método Doble Ciego , Humanos , Incidencia , Náusea y Vómito Posoperatorios/etiología , Estudios Prospectivos , Supositorios , Técnicas de Sutura
9.
Chin Med J (Engl) ; 105(4): 322-7, 1992 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-1618017

RESUMEN

Pingandan was a secret prescription for treatment of stomach upset, nausea and vomiting for emperors in the Qing Dynasty of China. This study was to compare the effects of Pingandan with those of scopolamine and dramamine on motion sickness (MS) and nystagmus. Fourteen cats were tested in a parallel swing (0.22 Hz, 3.9 m/S2) for 20 min, and then in a rotating chair (10 degrees/S2, 20 rpm) for 1-2 min. The effects of scopolamine 1 mg, dramamine 25 mg and three doses of Pingandan 50x, 30x, 10x of 0.45 g/kg were observed and compared to placebos. These drugs or placebos were administered to each cat 30-60 min prior to the tests. The post-rotary nystagmus and MS symptoms were recorded. The Suri's scale for MS severity, Latin square and double blind techniques were used. The interval between any two tests was 2-5 days. It was found that Pingandan 50x and scopolamine 1 mg were more effective than placebos in reducing MS symptoms (P less than 0.01) and suppressing slow phase velocity of nystagmus (P less than 0.05), while Pingandan 30x significantly reduced MS symptoms only (P less than 0.01). Pingandan 10x and dramamine 25 mg had no anti-MS effect. Chinese medicine Pingandan is an effective anti-MS drug.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Mareo por Movimiento/prevención & control , Nistagmo Patológico/prevención & control , Animales , Gatos , Dimenhidrinato/uso terapéutico , Femenino , Masculino , Escopolamina/uso terapéutico
10.
Acta Otolaryngol ; 108(3-4): 168-74, 1989.
Artículo en Inglés | MEDLINE | ID: mdl-2683568

RESUMEN

A controlled, double-blind study was carried out to determine whether nystagmus response to optokinetic or vestibular stimuli might be altered by some agent contained in powdered ginger root (Zingiber officinale). For comparative purposes, the test subjects were examined after medication with ginger root, placebo and with dimenhydrinate. Eye movements were recorded using standard ENG equipment and evaluation was performed by automatic nystagmus analysis. It could be demonstrated that the effect of ginger root did not differ from that found at baseline, or with placebo, i.e. it had no influence on the experimentally induced nystagmus. Dimenhydrinate, on the other hand, was found to cause a reduction in the nystagmus response to caloric, rotatory and optokinetic stimuli. From the present study it can be concluded that neither the vestibular nor the oculomotor system, both of which are of decisive importance in the occurrence of motion sickness, are influenced by ginger. A CNS mechanism, which is characteristic of the conventional anti-motion sickness drugs, can thus be excluded as regards ginger root. It is more likely that any reduction of motion-sickness symptoms derives from the influence of the ginger root agents on the gastric system.


Asunto(s)
Antieméticos/uso terapéutico , Dimenhidrinato/uso terapéutico , Mareo por Movimiento/tratamiento farmacológico , Plantas Medicinales , Adulto , Pruebas Calóricas , Método Doble Ciego , Electronistagmografía , Femenino , Humanos , Masculino , Nistagmo Fisiológico/efectos de los fármacos , Ensayos Clínicos Controlados Aleatorios como Asunto , Reflejo Vestibuloocular/efectos de los fármacos
11.
Clin Res Pr Drug Regul Aff ; 6(2): 129-36, 1988.
Artículo en Inglés | MEDLINE | ID: mdl-11538042

RESUMEN

UNLABELLED: Ginger and several other medications were compared with scopolamine and d-amphetamine for effectiveness in prevention of motion sickness. METHODS: Double-blind techniques were used. The subjects were given the medications two hours before they were rotated in a chair making head movements until a symptom total short of vomiting was reached. Standardized N.A.S.A. techniques were used for speed of rotation and end-point of motion sickness. RESULTS: The three doses of ginger were all at the placebo level of efficacy. Amitriptyline, ethopropazine and trihexyphenidyl increased the tolerated head movements but the increase was not statistically significant. Significant levels of protection were produced by dimenhydrinate, promethazine, scopolamine and d-amphetamine. Protection was further increased by combination of these latter drugs with d-amphetamine. Efficacy was greatest as the dose was increased. CONCLUSIONS: The medication of choice in this study was scopolamine 0.6 mg with d-amphetamine 10 mg. This combination provided good protection with acceptable side effects.


Asunto(s)
Antieméticos/uso terapéutico , Dextroanfetamina/uso terapéutico , Mareo por Movimiento/prevención & control , Plantas Medicinales/metabolismo , Administración Oral , Adolescente , Adulto , Antieméticos/administración & dosificación , Dimenhidrinato/administración & dosificación , Dimenhidrinato/uso terapéutico , Femenino , Humanos , Masculino , Mareo por Movimiento/tratamiento farmacológico , Prometazina/administración & dosificación , Prometazina/uso terapéutico , Rotación , Escopolamina/administración & dosificación , Escopolamina/uso terapéutico , Especias
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA